Inhibrx Biosciences, Inc. (INBX) stock
INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$74.33+5.27 (+7.63%)
Close on Nov 19, 2026Market cap $1.09BP/E –Yield –
Inhibrx Biosciences shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Inhibrx Biosciences's shares outstanding was 16M at Sep 30, 2026. For fiscal 2025 it was 15M, up 3.4% from the year before. The highest annual figure on record is 15M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 15M | +3.4% |
| FY2024 | Dec 31, 2024 | 15M | +27.2% |
| FY2023 | Dec 31, 2023 | 12M | +17.5% |
| FY2022 | Dec 31, 2022 | 10M | +5.5% |
| FY2021 | Dec 31, 2021 | 10M | +50.5% |
| FY2020 | Dec 31, 2020 | 6M | +39.1% |
| FY2019 | Dec 31, 2019 | 5M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 16M | +1.6% |
| Q2 FY2026 | Jun 30, 2026 | 16M | +1.3% |
| Q1 FY2026 | Mar 31, 2026 | 16M | +0.8% |
| Q4 FY2025 | Dec 31, 2025 | 16M | +0.4% |
| Q3 FY2025 | Sep 30, 2025 | 15M | +0.1% |
| Q2 FY2025 | Jun 30, 2025 | 15M | +4.5% |
| Q1 FY2025 | Mar 31, 2025 | 15M | +13.4% |
| Q4 FY2024 | Dec 31, 2024 | 15M | +14.4% |
| Q3 FY2024 | Sep 30, 2024 | 15M | +31.2% |
| Q2 FY2024 | Jun 30, 2024 | 15M | +35.7% |
| Q1 FY2024 | Mar 31, 2024 | 14M | +25.2% |
| Q4 FY2023 | Dec 31, 2023 | 14M | +25.0% |
| Q3 FY2023 | Sep 30, 2023 | 12M | +20.7% |
| Q2 FY2023 | Jun 30, 2023 | 11M | +11.8% |
| Q1 FY2023 | Mar 31, 2023 | 11M | +11.7% |
| Q4 FY2022 | Dec 31, 2022 | 11M | +12.2% |
| Q3 FY2022 | Sep 30, 2022 | 10M | +3.1% |
| Q2 FY2022 | Jun 30, 2022 | 10M | +3.2% |
| Q1 FY2022 | Mar 31, 2022 | 10M | +3.4% |
| Q4 FY2021 | Dec 31, 2021 | 10M | +1.6% |
| Q3 FY2021 | Sep 30, 2021 | 9M | +41.7% |
| Q2 FY2021 | Jun 30, 2021 | 9M | +108.4% |
| Q1 FY2021 | Mar 31, 2021 | 9M | +107.9% |
| Q4 FY2020 | Dec 31, 2020 | 9M | +109.2% |
| Q3 FY2020 | Sep 30, 2020 | 7M | +47.4% |
| Q2 FY2020 | Jun 30, 2020 | 5M | – |
| Q1 FY2020 | Mar 31, 2020 | 5M | – |
| Q4 FY2019 | Dec 31, 2019 | 5M | – |
| Q3 FY2019 | Sep 30, 2019 | 5M | – |
See a number that looks wrong?